BRAF and lung carcinoma: Now, dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) combination therapy is the preferred first-line therapy for the BRAF V600E-mutation-positive lung cancer according to the NCCN (National Comprehensive Cancer Network) guidelines.